

Richard P Koche

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5659951/publications.pdf>

Version: 2024-02-01

85
papers

10,955
citations

66315

42
h-index

71651

76
g-index

103
all docs

103
docs citations

103
times ranked

17592
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. <i>Nature</i> , 2007, 448, 553-560.	13.7	3,733
2	Genomewide Analysis of PRC1 and PRC2 Occupancy Identifies Two Classes of Bivalent Domains. <i>PLoS Genetics</i> , 2008, 4, e1000242.	1.5	878
3	ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression. <i>Cancer Cell</i> , 2012, 22, 180-193.	7.7	504
4	GC-Rich Sequence Elements Recruit PRC2 in Mammalian ES Cells. <i>PLoS Genetics</i> , 2010, 6, e1001244.	1.5	368
5	Reprogramming Factor Expression Initiates Widespread Targeted Chromatin Remodeling. <i>Cell Stem Cell</i> , 2011, 8, 96-105.	5.2	345
6	Loss of BAP1 function leads to EZH2-dependent transformation. <i>Nature Medicine</i> , 2015, 21, 1344-1349.	15.2	297
7	Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. <i>Journal of Experimental Medicine</i> , 2013, 210, 2641-2659.	4.2	278
8	DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. <i>Nature Medicine</i> , 2015, 21, 335-343.	15.2	200
9	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. <i>Nature Medicine</i> , 2016, 22, 1488-1495.	15.2	195
10	Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma. <i>Nature Genetics</i> , 2020, 52, 29-34.	9.4	193
11	Î±-Ketoglutarate links p53 to cell fate during tumour suppression. <i>Nature</i> , 2019, 573, 595-599.	13.7	187
12	The MicrobesOnline Web site for comparative genomics. <i>Genome Research</i> , 2005, 15, 1015-1022.	2.4	176
13	A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription. <i>Molecular Cell</i> , 2017, 67, 308-321.e6.	4.5	172
14	Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in <i>NPM1</i> Mutant Leukemia. <i>Cancer Discovery</i> , 2016, 6, 1166-1181.	7.7	171
15	H2A.Z landscapes and dual modifications in pluripotent and multipotent stem cells underlie complex genome regulatory functions. <i>Genome Biology</i> , 2012, 13, R85.	13.9	166
16	AF10 Regulates Progressive H3K79 Methylation and HOX Gene Expression in Diverse AML Subtypes. <i>Cancer Cell</i> , 2014, 26, 896-908.	7.7	153
17	Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition. <i>Clinical Cancer Research</i> , 2016, 22, 2470-2481.	3.2	147
18	ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. <i>Nature Genetics</i> , 2020, 52, 198-207.	9.4	140

#	ARTICLE	IF	CITATIONS
19	L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer. <i>Nature Cancer</i> , 2020, 1, 28-45.	5.7	137
20	A geneâ€environment-induced epigenetic program initiates tumorigenesis. <i>Nature</i> , 2021, 590, 642-648.	13.7	133
21	NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis. <i>Cancer Cell</i> , 2016, 30, 863-878.	7.7	111
22	Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation. <i>Cell Stem Cell</i> , 2019, 25, 682-696.e8.	5.2	106
23	Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma. <i>Nature Communications</i> , 2020, 11, 5823.	5.8	104
24	SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. <i>Blood</i> , 2017, 130, 2631-2641.	0.6	102
25	Hematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia. <i>Cell Stem Cell</i> , 2015, 17, 611-623.	5.2	97
26	A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response. <i>Cell</i> , 2018, 172, 1007-1021.e17.	13.5	97
27	LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPÎ±-dependent enhancers in AML. <i>Blood</i> , 2018, 131, 1730-1742.	0.6	92
28	Genome-scale screens identify JNKâ€JUN signaling as a barrier for pluripotency exit and endoderm differentiation. <i>Nature Genetics</i> , 2019, 51, 999-1010.	9.4	90
29	Developmental chromatin programs determine oncogenic competence in melanoma. <i>Science</i> , 2021, 373, eabc1048.	6.0	80
30	PGBD5 promotes site-specific oncogenic mutations in human tumors. <i>Nature Genetics</i> , 2017, 49, 1005-1014.	9.4	69
31	MLL-AF9â€ and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. <i>Journal of Clinical Investigation</i> , 2016, 126, 997-1011.	3.9	69
32	Peptidomimetic blockade of MYB in acute myeloid leukemia. <i>Nature Communications</i> , 2018, 9, 110.	5.8	68
33	FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. <i>Cancer Cell</i> , 2020, 38, 534-550.e9.	7.7	67
34	TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	64
35	MEF2C Phosphorylation Is Required forÂChemotherapy Resistance in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2018, 8, 478-497.	7.7	59
36	Synergistic targeting of <i>FLT3</i> mutations in AML via combined menin-MLL and FLT3 inhibition. <i>Blood</i> , 2020, 136, 2442-2456.	0.6	59

#	ARTICLE	IF	CITATIONS
37	A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1. <i>Cancer Discovery</i> , 2019, 9, 962-979.	7.7	58
38	SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies. <i>Cancer Discovery</i> , 2021, 11, 1158-1175.	7.7	57
39	ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. <i>Nature Communications</i> , 2017, 8, 15429.	5.8	55
40	PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN. <i>Cancer Discovery</i> , 2020, 10, 1742-1757.	7.7	55
41	Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. <i>Blood</i> , 2021, 137, 1377-1391.	0.6	51
42	Pluripotency transcription factors and Tet1/2 maintain Brd4-independent stem cell identity. <i>Nature Cell Biology</i> , 2018, 20, 565-574.	4.6	49
43	FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor. <i>Cancer Discovery</i> , 2018, 8, 234-251.	7.7	49
44	PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression. <i>Cell Reports</i> , 2019, 27, 294-306.e5.	2.9	49
45	Targeting the CALR interactome in myeloproliferative neoplasms. <i>JCI Insight</i> , 2018, 3, .	2.3	49
46	MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. <i>Haematologica</i> , 2015, 100, e190-e193.	1.7	45
47	Anatomic position determines oncogenic specificity in melanoma. <i>Nature</i> , 2022, 604, 354-361.	13.7	44
48	A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition. <i>Blood</i> , 2015, 126, 2547-2547.	0.6	42
49	Arid1a restrains Kras-dependent changes in acinar cell identity. <i>ELife</i> , 2018, 7, .	2.8	39
50	Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia. <i>ELife</i> , 2021, 10, .	2.8	37
51	MPP8 is essential for sustaining self-renewal of ground-state pluripotent stem cells. <i>Nature Communications</i> , 2021, 12, 3034.	5.8	35
52	Mutant FOXL2C134W Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors. <i>Cancer Research</i> , 2020, 80, 3466-3479.	0.4	29
53	LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms. <i>Cancer Discovery</i> , 2021, 11, 1398-1410.	7.7	29
54	2-hydroxyglutarate inhibits MyoD-mediated differentiation by preventing H3K9 demethylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 12851-12856.	3.3	28

#	ARTICLE	IF	CITATIONS
55	HiC-DC+ enables systematic 3D interaction calls and differential analysis for Hi-C and HiChIP. <i>Nature Communications</i> , 2021, 12, 3366.	5.8	27
56	DICER1 Is Essential for Self-Renewal of Human Embryonic Stem Cells. <i>Stem Cell Reports</i> , 2018, 11, 616-625.	2.3	24
57	Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition. <i>Cancer Discovery</i> , 2020, 10, 1500-1513.	7.7	24
58	Combined Targeting of the Menin-MLL1 Chromatin Complex and FLT3 As a Novel Therapeutic Concept Against NPM1 Mutant or MLL-Rearranged AML with Mutated FLT3. <i>Blood</i> , 2019, 134, 1441-1441.	0.6	18
59	CRISPR screening uncovers a central requirement for HHEX in pancreatic lineage commitment and plasticity restriction. <i>Nature Cell Biology</i> , 2022, 24, 1064-1076.	4.6	15
60	UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2103592118.	3.3	14
61	PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. <i>Cancer Discovery</i> , 2022, 12, 2120-2139.	7.7	14
62	Forward genetic screen of human transposase genomic rearrangements. <i>BMC Genomics</i> , 2016, 17, 548.	1.2	13
63	Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras. <i>Blood Advances</i> , 2018, 2, 2478-2490.	2.5	12
64	Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms. <i>Clinical Cancer Research</i> , 2021, 27, 3456-3468.	3.2	12
65	Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition. <i>Blood</i> , 2015, 126, 3792-3792.	0.6	11
66	Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". <i>Nature Medicine</i> , 2016, 22, 578-579.	15.2	7
67	Loss of H3K36 Methyltransferase SETD2 Impairs V(D)J Recombination during Lymphoid Development. <i>IScience</i> , 2020, 23, 100941.	1.9	6
68	Purification and Sequencing of Large Circular DNA from Human Cells. <i>Protocol Exchange</i> , 0, , .	0.3	6
69	Functional Profiling of Patient AML Stem Cells Reveals Mechanisms of Epigenetic Plasticity Controlling Therapy Resistance. <i>Blood</i> , 2018, 132, 1318-1318.	0.6	6
70	Genomic Dark Matter Sheds Light on EVI1-Driven Leukemia. <i>Cancer Cell</i> , 2014, 25, 407-408.	7.7	4
71	Genome-Wide RNAi Screen Identifies The Mechanistic Role For DOT1L In MLL-Rearranged Leukemia. <i>Blood</i> , 2013, 122, 598-598.	0.6	4
72	AML with Mutations in IDH1 and DNMT3A Exhibits a Distinct Epigenetic Signature with Poorer Overall Survival. <i>Blood</i> , 2018, 132, 1471-1471.	0.6	2

#	ARTICLE	IF	CITATIONS
73	The BMP/SMAD Pathway Is a Key Mediator of Leukemic Transformation of TP53-Mutant Post-MPN AML. Blood, 2021, 138, 626-626.	0.6	2
74	Loss of Lysine Histone Methyltransferase Setd2 Disrupts Normal Hematopoiesis, Lineage Commitment and Reveals a Novel Role for H3K36me3 in Immunoglobulin VDJ Recombination. Blood, 2016, 128, 423-423.	0.6	1
75	Non-Catalytic Role of SETD1A Regulates DNA Repair in Leukemia. Blood, 2016, 128, 434-434.	0.6	1
76	Regulation of HOX gene expression by AF10-mediated conversion of H3K79me1 to H3K79me2. Experimental Hematology, 2014, 42, S30.	0.2	0
77	Conditional Deletion of Asxl1 Results in Myelodysplasia. Blood, 2012, 120, 308-308.	0.6	0
78	BAP1 Loss Results in EZH2-Dependent Transformation in Myelodysplastic Syndromes. Blood, 2015, 126, 713-713.	0.6	0
79	An Epigenetic Regulator Screen Identifies Novel Targets That Sensitize MLL-Rearranged Leukemia to DOT1L Inhibition. Blood, 2016, 128, 571-571.	0.6	0
80	Aberrant Phosphorylation of MEF2C Is Dispensable for Hematopoiesis, and Induces Chemotherapy Resistance and Susceptibility to MARK Kinase Inhibition Therapy in Acute Myeloid Leukemia. Blood, 2016, 128, 436-436.	0.6	0
81	Inhibition of MEK and DDR Pathways Induces Synergistic Killing of Novel Mll-Af4 B-ALL Model Harboring Activated Ras Mutations. Blood, 2016, 128, 1511-1511.	0.6	0
82	The Lysine Histone Methyltransferase SETD2 Is Required for Appropriate Immunoglobulin VDJ Recombination. Blood, 2018, 132, 511-511.	0.6	0
83	Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism. Blood, 2019, 134, 109-109.	0.6	0
84	Single Cell ATAC Lineage Deconvolution Reveals Overlapping Subclones in Epigenetically Distinct AML Samples. Blood, 2021, 138, 2381-2381.	0.6	0
85	The High Mobility Group A1 Chromatin Regulator Drives Immune Evasion during MPN Progression By Repressing Genes Involved in Antigen Presentation and Immune Attack. Blood, 2021, 138, 2546-2546.	0.6	0